Acute Myeloid Leukemia
The Acute Myeloid Leukemia pipeline: 123 tracked drugs, 17 approved for this indication.
17 approved / phase 413 Phase 33 Phase 2/38 Phase 228 Phase 1/247 Phase 17 preclinical / unstaged
Compare the share prices of listed companies in Acute Myeloid Leukemia →
Total attributable cost
$4.5B
$199,362/patient
Drug spend
Not yet sourced
All stages, newly diagnosed (2026 incidence estimate) · US
The Acute Myeloid Leukemia pipeline
Key trial results for every approved and late-stage drug: Acute Myeloid Leukemia results by drug.